Hugging Face's logo

Spaces:
empirenexus
/
TranscriptWriting
Sleeping

App Files Community
TranscriptWriting / PSORIASIS_STUDY_README.md
jmisak's picture
jmisak
Upload 57 files
52d0298 verified
preview code
|
raw
history blame contribute delete
11.3 kB

A newer version of the Gradio SDK is available: 6.2.0

Upgrade

Psoriasis Study - Sample Data Documentation

Created: October 20, 2025 Purpose: Enterprise testing of TranscriptorAI market research capabilities

Overview

This directory contains 10 realistic HCP interview transcripts for a fictional psoriasis biologic drug called Dermovia (IL-17 inhibitor). These transcripts were created specifically to test the enhanced market research storytelling capabilities of TranscriptorAI v3.0.

Dataset Summary

Total Transcripts: 10

  • 6 Dermatologists (specialists)
  • 4 General Practitioners (primary care)

Total Size: 164K

  • Average length: ~16K per transcript
  • Word count range: 1,800 - 3,800 words
  • Total quotes extracted: 300 high-impact quotes

Transcript Details

Dermatologists (Specialists)

1. Dermatologist_01_Academic_Center.txt (13K)

  • Setting: Major Academic Medical Center, Boston
  • Experience: 18 years
  • Patient Volume: ~300 psoriasis patients
  • Key Themes: Clinical trial data, treatment algorithms, insurance barriers, efficacy vs safety trade-offs
  • Notable: Discusses head-to-head comparisons, secondary non-response, JAK inhibitor concerns

2. Dermatologist_02_Private_Practice.txt (14K)

  • Setting: Private Practice, Atlanta, GA
  • Experience: 12 years
  • Patient Volume: ~150 psoriasis patients, 35-40 on Dermovia
  • Key Themes: Real-world efficacy (70-75% PASI 90), serious adverse events, cost barriers, prior auth challenges
  • Notable: Reports depression and A-fib cases possibly related to treatment

3. Dermatologist_03_Community_Hospital.txt (8.3K)

  • Setting: Community Hospital, Phoenix, AZ
  • Experience: 25 years
  • Patient Volume: ~200 psoriasis patients, 25 on Dermovia
  • Key Themes: Quarterly dosing advantage for elderly patients, Crohn's disease case, compliance improvement
  • Notable: Discusses IBD screening protocols after adverse event

4. Dermatologist_04_Rural_Clinic.txt (16K)

  • Setting: Rural Health Clinic, Montana
  • Experience: 8 years
  • Patient Volume: ~80 psoriasis patients, 10-12 on Dermovia
  • Key Themes: Rural access barriers, in-office administration for all patients, power outage concerns
  • Notable: 100% in-office injection due to storage/convenience issues

5. Dermatologist_05_Teaching_Hospital.txt (18K)

  • Setting: Teaching Hospital, Chicago, IL
  • Experience: 6 years
  • Patient Volume: ~180 psoriasis patients, 30-35 on Dermovia
  • Key Themes: Clinical trial involvement, resident education, IBD screening, brodalumab REMS program
  • Notable: Academic perspective, research on predictive biomarkers

6. Dermatologist_06_West_Coast_Practice.txt (17K)

  • Setting: Private Practice, San Diego, CA
  • Experience: 15 years
  • Patient Volume: ~220 psoriasis patients, 45-50 on Dermovia
  • Key Themes: Tech industry insurance coverage, dose intensification, secondary loss of response
  • Notable: Highest patient volume on Dermovia, successful dose adjustment case

General Practitioners (Primary Care)

7. GP_01_Suburban_Practice.txt (13K)

  • Setting: Suburban Family Practice, Minneapolis, MN
  • Experience: 22 years
  • Patient Volume: ~50 psoriasis patients (mild to moderate)
  • Key Themes: Referral patterns, discomfort with biologics, role of primary care, education gaps
  • Notable: Honest about limitations, advocates for better CME training

8. GP_02_Urban_Clinic.txt (14K)

  • Setting: Urban Community Health Clinic, Detroit, MI
  • Experience: 10 years
  • Patient Volume: ~35 psoriasis patients
  • Key Themes: Underserved population, Medicaid/uninsured barriers, methotrexate use, access challenges
  • Notable: Never prescribed biologics due to cost/complexity barriers

9. GP_03_Military_Base.txt (15K)

  • Setting: Military Medical Center, San Antonio, TX
  • Experience: 14 years
  • Patient Volume: ~65 active duty/veteran patients
  • Key Themes: Military healthcare advantages, deployment challenges, TRICARE coverage, fitness-for-duty
  • Notable: Good formulary access, quarterly dosing valuable for deployments

10. GP_04_Rural_Healthcare.txt (15K)

  • Setting: Rural Health Network, Wyoming
  • Experience: 28 years
  • Patient Volume: ~45 psoriasis patients
  • Key Themes: Geographic isolation (140 miles to dermatologist), telemedicine limitations, pragmatic approach
  • Notable: Most experienced GP, discusses 28-year career perspective

Clinical Content Themes

Drug Profile: Dermovia (Fictional IL-17 Inhibitor)

  • Dosing: Every 12 weeks (quarterly) after loading dose
  • Efficacy: 70-75% PASI 90 at 16 weeks (real-world)
  • PASI 100: 30-40% complete clearance
  • Speed: Visible improvement by week 4-6
  • List Price: ~$82,000/year

Safety Profile Discussed:

  • Common: Candida infections (25-30%), injection site reactions (30-40%), URI (40-50%)
  • Serious: Pneumonia, cellulitis, neutropenia, possible IBD exacerbation (1-2%)
  • Rare: Depression/suicidality, atrial fibrillation, drug-induced lupus

Competitive Landscape:

  • IL-17 Inhibitors: Ixekizumab (every 2-4 weeks), Secukinumab (monthly), Brodalumab (highest efficacy, black box warning)
  • IL-23 Inhibitors: Risankizumab, Guselkumab (safer GI profile, slower onset)
  • JAK Inhibitors: Deucravacitinib (oral, FDA warnings for thrombosis/malignancy)
  • TNF Inhibitors: Adalimumab (older, biosimilars available)

Insurance/Access Barriers:

  • Prior Auth: 50-60% first-try approval, 3-6 week delays common
  • Copay Cards: Reduce cost to $5-25/dose for commercial insurance
  • Medicare Gap: No copay assistance, $2,000-5,000/year out-of-pocket
  • Step Therapy: Often required to fail topicals/methotrexate first

Quote Extraction Results

Total Quotes: 300 (30 per transcript)

Impact Score Range: 0.80 - 0.95

Theme Distribution:

  1. Patient Management: 100 quotes (33%)
  2. General: 77 quotes (26%)
  3. Prescribing: 34 quotes (11%)
  4. Barriers: 24 quotes (8%)
  5. Efficacy: 23 quotes (8%)
  6. Safety: 20 quotes (7%)
  7. Diagnosis: 14 quotes (5%)
  8. Competitive: 8 quotes (3%)

Top Quotes by Impact Score:

Score 0.95:

"I've been using Dermovia since it launched, so about 16 months now. I was excited about it from the beginning because the Phase 3 data looked impressive. The 75% PASI 90 rate put it right in line with ixekizumab, which had been my go-to IL-17 inhibitor. But the quarterly dosing was the real selling point."

Score 0.90:

"For biologic-naive patients under 65 with no major comorbidities, my first choice is often an IL-17 inhibitor like Dermovia or ixekizumab."

Score 0.90:

"Where Dermovia wins is convenience. I've had patients switch from every-two-week injections to every-12-weeks, and they absolutely love it."

Use Cases for Testing

1. Cross-Transcript Analysis

  • Identify consensus themes across dermatologists vs GPs
  • Compare urban/rural/academic/military perspectives
  • Track efficacy/safety signals across all interviews

2. Quote-Based Storytelling

  • 300 high-impact quotes ready for weaving into narratives
  • Varied perspectives (specialist confidence vs GP hesitancy)
  • Patient impact stories embedded in clinical discussions

3. Market Research Insights

  • Clear unmet needs (access, cost, prior auth burden)
  • Competitive positioning (quarterly dosing = key differentiator)
  • Safety concerns (IBD risk, infections) with real examples

4. Report Generation Testing

  • Executive summaries with "THE HEADLINE"
  • Data → Implication → Action structure
  • Visual callouts for key statistics
  • Recommendations with priority levels (IMMEDIATE/30-day/90-day)

Data Quality Features

Realism:

✅ Authentic medical terminology and clinical discussions ✅ Realistic PASI scores and efficacy percentages ✅ Genuine insurance/access barrier scenarios ✅ Varied physician perspectives based on practice setting ✅ Mix of enthusiasm, caution, and frustration

Storytelling Elements:

✅ Direct patient quotes embedded in HCP narratives ✅ Specific case examples with outcomes ✅ Emotional language ("life-changing," "heartbreaking," "game-changer") ✅ Numerical data for credibility (75% PASI 90, $82K/year, 3-6 week delays) ✅ Comparative statements for context

Diversity:

✅ 6 different geographic regions (Boston, Atlanta, Phoenix, Montana, Chicago, San Diego, Minneapolis, Detroit, San Antonio, Wyoming) ✅ 4 practice settings (academic, private, community, rural, military, urban clinic) ✅ Experience range: 6-28 years ✅ Patient volumes: 35-300 psoriasis patients ✅ Specialist expertise vs generalist pragmatism

Testing Status

✅ Completed:

  • All 10 transcripts created (164K total)
  • Quote extraction tested (300 quotes extracted successfully)
  • Syntax validation passed (all files have valid Python syntax)
  • Code formatting checked

🔄 Ready for:

  • Full analysis pipeline run through TranscriptorAI
  • Cross-transcript summary generation
  • Narrative report generation (PDF/Word/HTML)
  • Quote weaving and storytelling validation
  • Visual callout box rendering

📊 Expected Outputs:

  1. CSV: Structured data with quality scores, word counts, themes
  2. PDF Report: Cross-transcript insights with embedded quotes
  3. Narrative Report: Executive summary with "THE HEADLINE" and recommendations
  4. HTML Dashboard: Interactive visualization of themes and findings

File Locations

Transcripts: /home/john/TranscriptorEnhanced/sample_data/psoriasis_study/ Test Scripts: /home/john/TranscriptorEnhanced/test_psoriasis_quotes.py Quote Extractor: /home/john/TranscriptorEnhanced/quote_extractor.py Main App: /home/john/TranscriptorEnhanced/app.py

Notes for Analysis

Key Insights to Look For:

  1. Quarterly dosing mentioned as key differentiator by nearly all HCPs
  2. Insurance/prior auth cited as biggest barrier by 100% of respondents
  3. Efficacy consensus: 70-75% PASI 90 real-world (vs 75% in trials)
  4. Safety concerns: IBD risk for IL-17 class, infections manageable
  5. Access disparity: Urban/academic vs rural/underserved populations

Narrative Hooks:

  • Rural dermatologist: "One patient told me, 'Doc, I haven't seen my skin this clear in 15 years.'"
  • Urban GP: "The list price is $70,000-80,000 a year. That's not happening for my population."
  • Teaching hospital: "Every week of delay is another week of suffering for the patient."

Business Implications:

  • Strength: Quarterly dosing = competitive advantage
  • Weakness: Same safety/efficacy as competitors = parity positioning
  • Opportunity: Target rural/compliance-challenged populations
  • Threat: Prior auth burden reducing market access

Status: ✅ Ready for enterprise production testing Last Updated: October 20, 2025 Version: 1.0